最新ニュース Franklin FTSE Germany ETF (ARCA:FLGR)

Franklin FTSE Germany ETF

Financial Services

Industrials

Technology

Consumer Cyclical

Basic Materials

Healthcare

Communication Services

Utilities

Consumer Defensive

Real Estate

Under normal market conditions, the Fund invests at least 80 percent of its assets in the component securities of the FTSE Germany Capped Index and in depositary receipts representing such securities. The FTSE Germany Capped Index is a free float-adjusted market capitalization weighted index maintained and calculated by FTSE Russell with a capping methodology applied quarterly to issuer weights so that no single issuer of a component exceeds 25 percent of the FTSE Germany Capped Index weight, and all issuers with weights above 5 percent do not cumulatively exceed 50 percent of the FTSE Germany Capped Indexs weight. The FTSE Germany Capped Index is based on the FTSE Germany Index and is designed to measure the performance of German large- and mid-capitalization stocks. FTSE Russell determines eligible securities for the FTSE Germany Capped Index based on measures such as the companys place of incorporation, listing country, investor protection regulations present in the country of incorporation, tax domicile, location of headquarters/factors of production and currency of denomination.

Sap Se Common Stock Eur

Siemens AG

AHP:APH

Deutsche Telekom AG Na

Infineon Technolog

ViiV Healthcare announced Wednesday the latest findings from its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">EMBRACE phase 2b study</a>.
The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), kept viral levels suppressed in adults living with HIV who were already <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44280792/viiv-healthcares-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-s" rel="noreferrer noopener">stable on treatment</a>.
These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
Results from the EMBRACE study at the six-month primary endpoint showed:
<ul>
<li>96% of participants receiving VH109 60mg/kg intravenously (IV) and 88% receiving VH109 3000mg subcutaneously (SC) with rHuPH20 maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group.</li>
</ul>
<ul>
<li>Overall, 4% of the IV group and 6% of the SC group had HIV-1 RNA levels of 50 copies/mL or higher when measured at month six, compared to none in the standard-of-care group.</li>
</ul>
<ul>
<li>VH109 was generally well tolerated, though infusion site reactions were more frequent with SC administration, occurring in 14% compared to none with IV administration.</li>
</ul>
<ul>
<li>ViiV Healthcare will progress a six-month IV formulation of VH109 in combination with CAB LA for further evaluation in an EMBRACE part two trial.</li>
</ul>
The company also presented data from two phase 2a proof-of-concept studies of investigational antiretroviral therapies, VH4524184 <a href="https://www.benzinga.com/pressreleases/25/03/b44261960/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-" target="_blank" rel="noreferrer noopener">(VH184) and VH4011499 (VH499)</a>.
Also Read: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39915897/pfizer-and-gsks-viiv-healthcares-two-drug-hiv-treatment-matches-gileads-three-drug-combo-in-major" target="_blank" rel="noreferrer noopener">Pfizer And GSK&#8217;s ViiV Healthcare&#8217;s Two-Drug HIV Treatment Matches Gilead&#8217;s Three-Drug Combo In Major Trial</a></li>
</ul>
VH184 demonstrated potency at all doses. After 10 days of monotherapy, the average decreases were -1.17, -2.15, and -2.31 log10 copies/mL for the 10mg, 50mg, and 300mg doses, respectively.
<ul>
<li>The maximum viral load decline (-2.69 log10) was observed in the 300mg dose. Additionally, no drug-resistance mutations were observed at the end of the study.</li>
<li>Long-acting formulations of VH184 in adults without HIV are being evaluated in an ongoing phase 1 study.</li>
</ul>
<ul>
<li>The trial of VH499 showed that all oral doses (25mg, 100mg, and 250mg) led to a decrease in HIV-1 viral load ranging from -2.2 log10 copies/mL in the 250mg arm to -1.8 log10 copies/mL in the 25mg and 100mg arms. VH499 was well tolerated, with all adverse events being mild to moderate in severity.</li>
<li>There were no adverse events leading to withdrawal, and no serious adverse events were reported</li>
<li>On day 11, one individual on the 25mg dose developed a single mutation associated with reduced susceptibility to capsid inhibitors.</li>
</ul>
ViiV Healthcare is majority owned by GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Shionogi as shareholders.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44282015/cannabis-firm-cresco-labs-reports-mixed-q4-ceo-says-company-will-strategically-deploy-capital-to-create-growth-in-2025" target="_blank" rel="noreferrer noopener">Cannabis Firm Cresco Labs Reports Mixed Q4, CEO Says Company Will &#8216;Strategically Deploy Capital To Create Growth&#8217; In 2025</a></li>
</ul>

Biotech

Large Cap

News

Health Care

General

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study

Management

NDAQ

Nasdaq And Adena T. Friedman Enter Employment Agreement Relating To  Continuation Of Her Role As Chair And CEO Through January 1, 2030 - Filing

Earnings

SCYX

SCYNEXIS 2024 GAAP EPS $(0.44) Down From $1.39 YoY, Sales $3.75M Down From $140.14M YoY

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 20 years by 1.24% on an annualized basis producing an average annual return of 9.33%. Currently, Graphic Packaging Holding has a market capitalization of $7.88 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 20 years ago, it would be worth $5,618.84 today based on a price of $26.24 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741814238_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Graphic Packaging Holding Stock In The Last 20 Years

LEGH

Legacy Housing FY24 Revenue $184.2M, Down 2.6% YoY

On March 12, 2025, the Board of Directors of Kewaunee Scientific amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023.&nbsp;
The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended, which does not have a specified expiration date.&nbsp;
The Program, as of the end of day March 12, 2025 and prior to this amendment, still had 11,176 shares authorized for repurchase which remain authorized for repurchase and are unaffected by this amendment.

Buybacks

KEQU

Kewaunee Scientific Amends Share Repurchase Program, Authorizing Up To An Additional 100,000 Shares

The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses.

ARMP

Armata Enters $10M Secured Credit Agreement With Innoviva Strategic Opportunities LLC

Piper Sandler has upgraded Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a molecular diagnostic testing and precision medicine company.
Analyst David Westenberg says Myriad Genetics&#8217; management team set an overly aggressive LRP. Since then, two events—the loss of a private payer&#8217;s reimbursement on Genesight and an NCCN guideline language change—have led to an over 50% decline in the stock in the last six months.
Westenberg writes that Myriad Genetics risks missing this year&#8217;s guidance and might need to set 2026 expectations below the LRP.
&#8220;We think Myriad&#8217;s biggest remaining potential downside is expectations set by a previous CEO, and we believe the stock will find a bottom around this ~1x revenue range,&#8221; Piper Sandler writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43953008/myriad-genetics-faces-cost-restructuring-as-unitedhealthcare-ends-genesight-coverage-appoints-new-ceo" rel="noreferrer noopener">Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO</a>
BMO Capital writes Myriad Genetics has faced challenges in the urology and prostate testing market, losing some ground to Deciphera Pharmaceuticals and Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) in recent years.
However, the company has taken steps to stand out, including a new partnership with PATHOMIQ to integrate AI with molecular testing. Myriad Genetics plans to launch a test for patients after radical prostatectomy and radiation treatment later this year or early next year. This test will be offered alongside Prolaris as a combined option.
Piper Sandler writes that the stock has stabilized, allowing new CEO Sam Raha to reshape the business, set clear strategies and align expectations. The analyst has upgraded the stock from Neutral to Overweight, with a price target of $12.50, <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">up from $11.50</a>.
Price Action: MYGN stock is up 2.44% at $10.50 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" target="_blank" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a></li>
</ul>

Analyst Color

Upgrades

Analyst Ratings

MYGN

VCYT

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon is no stranger to making bold predictions about the economy. His latest comments suggest storm clouds <a href="https://www.benzinga.com/25/03/44270128/us-recession-probability-escalates-to-35-amid-tariffs-pimco-sounds-alarm">could be forming once again</a>.
What To Know: At the 2025 National Retirement Summit hosted by BlackRock and Semafor on Wednesday, Dimon warned that he sees a weakening of the economy and negative sentiment, according to an X <a href="https://x.com/SpencerHakimian/status/1899879996304273725">post</a> from Tolou Capital Management founder Spencer Hakimian. The post also indicates that Dimon believes tariffs are causing uncertainty.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x2A;JP MORGAN&#39;S CEO DIMON: SEEING WEAKENING IN ECONOMY, NEGATIVE SENTIMENT &#x2A;DIMON SAYS TARIFFS ARE CAUSING UNCERTAINTY Most important private sector human on earth telling it to you straight up.
&mdash; Spencer Hakimian (@SpencerHakimian) <a href="https://twitter.com/SpencerHakimian/status/1899879996304273725?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Semafor Principals editor Morgan Chalfant also reported similar details from the event in a separate X <a href="https://x.com/mchalfant16/status/1899878158389719290">post</a>. Chalfant noted that although Dimon said <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">consumer sentiment is weakening</a>, the JPMorgan chief indicated that he doesn&#8217;t believe the average American &#8220;changes what they&#8217;re going to do&#8221; because of tariffs.
Dimon isn&#8217;t always spot-on with his predictions. In late 2022, he warned that an <a href="http://www.benzinga.com/news/22/10/29208975/jamie-dimon-warns-of-u-s-recession-in-6-9-months-says-jp-morgan-preparing-for-economic-hurricane" target="_blank" rel="noreferrer noopener">economic &#8220;hurricane&#8221;</a> was coming in mid-2023.
Dimon later walked back those comments after data showed otherwise.
&#8220;I shouldn't ever use the word hurricane, but &#8230; there were storm clouds,&#8221; Dimon <a href="https://www.benzinga.com/news/23/01/30358567/i-shouldnt-ever-use-the-word-hurricane-jamie-dimon-says-storm-clouds-remain-but-the-consumer-is-roll">said</a> in a 2023 interview.
It&#8217;s not clear if Dimon sees &#8220;storm clouds&#8221; over the economy this time around, but he at least appears to be taking a cautious stance. 
Price Action: <a href="http://benzinga.com/quote/jpm">JPMorgan shares</a> were up 0.61% at $230.50 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44280431/cpi-reactions">Inflation Moves In The &#8216;Right Direction&#8217; But Forecast Is Hazy, Economist Says</a></li>
</ul>
Photo: Shutterstock.

Events

Jamie Dimon Warns Of Economic Weakening, Negative Consumer Sentiment

<h3>Gainers</h3>
<ul>
<li>Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) stock moved upwards by 9.1% to $2.15 during Wednesday's after-market session. The market value of their outstanding shares is at $109.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) shares increased by 6.47% to $1.81. The market value of their outstanding shares is at $581.7 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) stock increased by 5.51% to $3.06. The company's market cap stands at $402.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares rose 5.0% to $0.43. The company's market cap stands at $7.3 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares increased by 4.99% to $0.58. The company's market cap stands at $5.7 million. </li>
<li>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) stock increased by 4.82% to $0.5. The company's market cap stands at $35.3 million. The company's, Q4 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) stock declined by 14.0% to $0.03 during Wednesday's after-market session. The company's market cap stands at $16.5 million. </li>
<li>Starbox Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) stock decreased by 5.9% to $0.27. The market value of their outstanding shares is at $2.0 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) stock fell 5.34% to $0.53. The company's market cap stands at $7.2 million. </li>
<li>Haoxi Health Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) stock declined by 5.2% to $1.46. The market value of their outstanding shares is at $4.1 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares fell 4.47% to $1.93. The company's market cap stands at $43.7 million. </li>
<li>Able View Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABLV#NASDAQ">ABLV</a>) stock declined by 4.35% to $1.1. The market value of their outstanding shares is at $54.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABLV

ASST

BHAT

CDLX

CMLS

MITQ

SEAT

STBX

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock increased by 17.4% to $2.46 during Wednesday's after-market session. The market value of their outstanding shares is at $104.0 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock moved upwards by 16.23% to $2.65. The market value of their outstanding shares is at $2.7 million. As per the press release, Q4 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock increased by 12.64% to $0.8. The market value of their outstanding shares is at $18.4 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) shares moved upwards by 12.41% to $1.46. The company's market cap stands at $12.5 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares rose 8.99% to $0.29. The company's market cap stands at $1.8 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock rose 8.19% to $0.75. The company's market cap stands at $128.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock decreased by 52.5% to $0.05 during Wednesday's after-market session. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares declined by 39.27% to $0.03. The company's market cap stands at $2.7 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 18.86% to $0.04. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares fell 9.98% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) stock declined by 9.76% to $3.7. The company's market cap stands at $115.1 million. As per the press release, Q4 earnings came out today. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 7.03% to $0.25. The company's market cap stands at $4.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

BSGM

BTMD

CPHI

CUTR

HEPA

HURA

MCRB

SCNX

SNES

SYRS

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock moved upwards by 30.4% to $0.71 during Wednesday's after-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) stock moved upwards by 13.8% to $7.09. The company's market cap stands at $133.9 million. The company's, Q4 earnings came out today. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) shares moved upwards by 6.22% to $0.51. The market value of their outstanding shares is at $16.6 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares increased by 5.92% to $0.18. The market value of their outstanding shares is at $23.9 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares increased by 5.45% to $2.9. The company's market cap stands at $7.2 million. </li>
<li>T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) shares moved upwards by 5.28% to $1.59. The market value of their outstanding shares is at $223.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) stock fell 11.3% to $15.83 during Wednesday's after-market session. The market value of their outstanding shares is at $120.2 million. The company's, Q4 earnings came out today. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares decreased by 9.93% to $0.29. </li>
<li>CDT Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) stock declined by 9.1% to $1.3. The company's market cap stands at $13.9 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock fell 7.77% to $0.57. The market value of their outstanding shares is at $17.0 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock fell 6.98% to $1.6. The company's market cap stands at $89.2 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares fell 4.78% to $0.47. The company's market cap stands at $11.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

CAPT

CDTG

HTCO

POLA

PSIG

RAIL

RCMT

SGBX

VSTE

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares rose 11.5% to $23.06 during Wednesday's after-market session. The market value of their outstanding shares is at $99.8 billion. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares rose 8.79% to $0.37. The market value of their outstanding shares is at $2.5 million. </li>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock rose 7.14% to $1.35. The company's market cap stands at $49.5 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) shares moved upwards by 6.66% to $1.44. The market value of their outstanding shares is at $120.3 million. </li>
<li>Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) stock rose 6.63% to $2.25. The company's market cap stands at $237.8 million. </li>
<li>CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) shares moved upwards by 6.22% to $7.0. The company's market cap stands at $942.8 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) stock fell 16.1% to $16.2 during Wednesday's after-market session. The market value of their outstanding shares is at $5.2 billion. The company's, Q4 earnings came out today. </li>
<li>Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) stock fell 15.51% to $1.8. The company's market cap stands at $52.4 million. As per the press release, Q2 earnings came out today. </li>
<li>UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) stock declined by 15.14% to $10.04. The market value of their outstanding shares is at $5.5 billion. As per the press release, Q4 earnings came out today. </li>
<li>A10 Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) shares declined by 10.54% to $17.49. The market value of their outstanding shares is at $1.2 billion. </li>
<li>NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) shares decreased by 10.42% to $9.2. The market value of their outstanding shares is at $1.2 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) stock decreased by 6.98% to $3.3. The company's market cap stands at $31.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATEN

CINT

CMTL

INTC

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTX

PATH

SatixFy Communications Ltd. Ordinary Share

SATX

TZUP

12 Information Technology Stocks Moving In Wednesday's After-Market Session

MTAL

MAC Copper Amends Debt And Further Simplifies Balance Sheet Through Early Repayment Of Sprott Mezzanine Facility

Groupon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares are trading higher Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/25/03/44263961/groupon-stock-moves-higher-after-q4-earnings-company-says-momentum-has-carried-into-2025">fourth-quarter results. </a>
What To Know: The company reported revenue totaling $130.38 million, surpassing the $127.74 million estimate. Despite a 4% year-over-year decline in revenue, the results were bolstered by a sequential rebound in unit sales and cash flow generation.
The company also reported a fourth-quarter loss of $1.20 per share, worse than the estimated loss of four cents per share, but it noted significant improvements in other key metrics. Gross billings were down 1% year-over-year, but Groupon ended the quarter with $228.8 million in cash and cash equivalents.
CEO Dusan Senkypl emphasized the company's successful transformation strategy, noting North America Local experienced growth in the quarter, positioning Groupon well for continued momentum into 2025. The company's focus on enhancing customer retention, expanding in key markets and improving merchant success is expected to drive further growth, with guidance for first-quarter revenue of $114 million to $117 million.
The company's shift to a mobile-first platform and focus on high-impact categories are expected to support its performance moving forward.
GRPN Price Action: Groupon shares were up 43.09% at $13.98 at market close Wednesday, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-1024x528.png" alt="" class="wp-image-821523" style="width:397px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41.png 1534w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44283118/tesla-loses-ground-in-us-ev-market-while-rivals-accelerate-ahead-in-january-report">Tesla Loses Ground in US EV Market While Rivals Accelerate Ahead in January: Report</a></li>
</ul>
Photo: Shutterstock

GRPN

Groupon Shares Are Up Today: What's Going On?

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) released its fourth-quarter results after Wednesday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/03/b44288526/uipath-acquires-peak-to-launch-vertically-specialized-agents-within-its-agentic-automation-platfor"> from the report.&nbsp;&nbsp;</a>
The Details: UiPath reported quarterly earnings of nine cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue of $424 million missed the analyst consensus estimate of $425.36 million and is an increase over revenue of $405.25 million from the same period last year.
Read More: <a href="https://www.benzinga.com/general/social-media/25/03/44286296/trump-media-technology-stock-drops-50-since-inauguration-day">Trump Media &amp; Technology Stock Drops 50% Since Inauguration Day</a>&nbsp;
For the fourth quarter, UiPath reported: 
<ul>
<li>ARR of $1.666 billion as of Jan. 31, 2025, increased 14 percent year-over-year.</li>
<li>Net new ARR&nbsp;of $60 million.</li>
<li>Dollar based net retention rate&nbsp;of 110%.</li>
<li>Non-GAAP gross margin&nbsp;was 87%. </li>
</ul>
&#8220;Fiscal 2025 was our most innovative year in recent history, introducing a wealth of new AI capabilities, and redefining the future of automation through our groundbreaking new products: Autopilot, Agent Builder, Agentic Orchestration, and Agentic Testing,&#8221; said Daniel Dines, UiPath CEO.
The company also announced the acquisition of Peak, an AI-native company, but did not disclose the specific terms of the deal. 
&#8220;With the acquisition of Peak, we are accelerating our mission to strengthen our vertical AI solutions strategy,&#8221; said Dines. 
Outlook:&nbsp;UiPath sees first-quarter revenue in a range of $330 million to $335 million, versus the $368.08 million estimate. 
PATH Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, UiPath shares are down 14.37% after hours at $10.13 Wednesday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

UiPath Shares Plunge After Q4 Revenues Miss, Weak Q1 Guidance

When President Trump announced a 50% tariff on Canadian aluminum and steel imports, it created a cloud of fear and <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">uncertainty in the markets</a>. 
Stocks dropped as the 25% previously announced tariffs set to be implemented on Wednesday were anticipated to be doubled.
Trump later hinted at reconsideration after Ontario's premier suspended a surcharge on electricity exports. While domestic producers may benefit, higher costs could dent the profits of industries that rely heavily on these materials.
Also Read: <a href="https://www.benzinga.com/news/25/03/44253100/trump-slaps-50-tariff-on-canadian-steel-aluminum-threatens-auto-industry">Trump Slaps 50% Tariff On Canadian Steel &amp; Aluminum, Threatens Auto Industry</a>
This has presented a good opportunity to look into exchange-traded funds, <a href="https://www.benzinga.com/etfs">ETFs, that may gain or lose</a>:
<ul>
<li>VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>): The ETF gained 1.3% on Tuesday. Its U.S. exposure is at 53.78%, with Brazil and Australia following at 14.65% and 10.71%, respectively. SLX has the least exposure to Canada at less than 1%. The ETF carries an expense ratio of 56 basis points. Tariffs on materials imports from Canada bode well for domestic producers. SLX has exposure to United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) and Steel Dynamics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>).</li>
</ul>
<ul>
<li>iShares U.S. Basic Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYM#NYSE">IYM</a>): This fund appeals to investors seeking a conservative way to gain aluminum exposure. The ETF&#8217;s exposure is spread out to base metals stocks and other materials sectors like chemicals and forestry products. This makes it a less speculative investment. This reduces risks from an aluminum market downturn. The ETF holds stocks of aluminum leaders such as Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) and Reliance Steel &amp; Aluminum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>). Both stand to gain if the tariffs are implemented.</li>
</ul>
<ul>
<li>The Invesco Building &amp; Construction ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKB#NYSE">PKB</a>): One of the outcomes of the 50% (or even 25%) tariffs on steel and aluminum imported from Canada is that it will drive up materials prices in the U.S. Higher steel prices may weigh on the construction sector. This fund could face profitability issues as steel is a key raw material in the industry it is exposed to.</li>
</ul>
<ul>
<li>The Invesco Food &amp; Beverage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBJ#NYSE">PBJ</a>): This fund could see headwinds as higher aluminum costs may pressure the food and beverage bottling industry as well. Companies like Diageo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>), Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), and PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) likely to face increased costs.</li>
</ul>
<h2 class="wp-block-heading">U.S. Steel Industry Backs The Move</h2>
Despite the market jitters, U.S. steel manufacturers are largely in favor of the tariffs. In a <a href="https://www.steel.org/2025/03/five-steel-groups-pledge-support-for-steel-tariffs-applaud-actions/">letter </a>to the president, five steel industry executives, represented by American Iron and Steel Institute, expressed their strong support for the 25% tariffs. Moreover,&nbsp;Jesse Gary, the CEO of&nbsp;Century Aluminum&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">told the New York Times</a>, &#8220;The new tariffs will close those loopholes back up and enable us to begin investing again, and bring on more production here in the U.S.&#8221;
While steel producers in the U.S. are supportive, the aluminum industry has shown a mixed reaction. Alcoa CEO William Oplinger <a href="https://www.investopedia.com/alcoa-s-ceo-says-trump-tariffs-could-wipe-out-100-000-u-s-jobs-11686292">voiced </a>concerns that tariffs could hurt the U.S. aluminum sector due to the company's strong ties to Canadian operations.
The impact of tariffs will likely trickle down to consumers as well. Domestic steel prices have already surged from around $700 to nearly $1,000 per ton since Trump's initial announcement in February. A Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-03-11/trump-s-metal-tariffs-set-to-hit-favorites-like-baseball-bats-and-fishing-reels">report </a> said that higher costs could affect a range of products, from aluminum baseball bats to stainless steel cookware and fishing reels.
Investors should keep an eye on ETFs exposed to these sectors, as they may see significant movement in the coming weeks. Whether Trump follows through with the full 50% tariff or retreats from the threat, the ripple effects will be felt across multiple industries and investment tools.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/03/44285737/dailydelta-rolls-out-etfs-for-daily-nasdaq-100-index-movements">DailyDelta Rolls Out ETFs For Daily Nasdaq-100 Index Movements</a></li>
</ul>
Image: Midjourney

Sector ETFs

ETFs

CENX

iShares Trust Dow Jones US Basic Materials Sector Index Fund

PowerShares ETF Trust Dynamic Building &nstruction Portfolio

STLD

Steel & Aluminum Import Tariff Threat: 4 ETFs Gaining & Losing In The Market Shake-Up

Ratings for Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of $30.00, and a low estimate of $5.73. This current average represents a 21.13% decrease from the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741813448_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Voyager Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Pete Stavropoulos</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$5.73</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Voyager Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Voyager Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Voyager Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Voyager Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VYGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Voyager Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Voyager Therapeutics</h2>
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
<h3>A Deep Dive into Voyager Therapeutics's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Voyager Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 433.79%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Voyager Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -36.72%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Voyager Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -2.72%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.1%, the company showcases effective utilization of assets.
Debt Management: Voyager Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VYGR

A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts

Bitcoin and Ethereum struggle to maintain gains, while XRP rallies on optimism over the SEC potentially closing its case against Ripple. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$82,997.45</td>
<td>-0.13%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,876.24</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$124.56</td>
<td>-2.1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.23</td>
<td>+2.5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1689</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001229</td>
<td>+0.8%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 5.2% and daily active addresses falling by 3.4%. Transactions greater than $100,000 are down from 11,844 to 10,766 in a single day. Exchanges netflows are down by 100.9%.</li>
<li>Coinglass data reports 97,058 traders were liquidated in the past 24 hours for $281.42 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44281794/binance-secures-2-billion-investment-from-abu-dhabi-mgx">Binance Secures $2 Billion Investment From Abu Dhabi MGX</a></li>
<li><a href="https://in.benzinga.com/25/03/44281569/rumble-buys-bitcoin-a-valuable-hedge-against-inflation">Rumble Buys Bitcoin: &#8216;A Valuable Hedge Against Inflation&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44272805/bitwise-launches-etf-tracking-firms-with-over-1000-bitcoin">Bitwise Launches ETF Tracking Firms With Over 1,000 Bitcoin</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44275216/bitcoin-to-defy-trump-tariffs-recession-fears-will-hit-200000-by-end-of-2025-standard-chartered">Bitcoin To Defy Trump Tariffs, Recession Fears, Will Hit $200,000 By End Of 2025: Standard Chartered</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44280122/after-vladimir-putin-said-nobody-can-ban-bitcoin-the-bank-of-russia-is-looking-to-allow-crypto-purchases">After Vladimir Putin Said &#8216;Nobody Can Ban Bitcoin&#8217;, The Bank Of Russia Is Looking To Allow Crypto Purchases</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Pi (CRYPTO: PI)</td>
<td>&nbsp;$1.70</td>
<td>+21.5%</td>
</tr>
<tr>
<td>Celestia (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TIA</a>)</td>
<td>&nbsp;$3.58</td>
<td>+16%</td>
</tr>
<tr>
<td>Story (CRYPTO: IP)</td>
<td>&nbsp;$6.04</td>
<td>+9.7%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Intuitio <a href="https://x.com/intuitio_/status/1899854521553006880">argues</a> that Bitcoin has only had a taste of the bull market, while Ethereum never truly experienced one—it was merely in an echo bubble that has now deflated. 
With BTC retesting its previous all-time high, he believes the claim that "the bull run hasn't even begun" may hold weight.
Jelle <a href="https://x.com/CryptoJelleNL/status/1899839832035058101">sees</a> bears still in control, noting that Monday's highs were swept, followed by a lower low after a series of higher lows.
 He warns that when bearish setups play out cleanly, there's no reason to chase short-term upside—instead, patience is key.
Moustache aka El Crypto Prof points out that the last time the S&amp;P 500's daily RSI was this low, Bitcoin rallied over 300% afterward. With both BTC and the S&amp;P 500 touching a key trendline, he believes this could be a bullish signal.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> The last time the RSI in the S&amp;P 500 (D) was this low, <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> rose more than 300% thereafter. -Both assets are also touching a very important trend line Be more bullish guys. <a href="https://t.co/SLuHrzk7ZF">pic.twitter.com/SLuHrzk7ZF</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$TIA

$XRP

Bitcoin, Ethereum Slip, XRP, Dogecoin Hold Gains On Slow Wednesday

Analysts' ratings for United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $129.22, along with a high estimate of $140.00 and a low estimate of $110.00. This upward trend is evident, with the current average reflecting a 8.99% increase from the previous average price target of $118.56.
<img src="https://www.benzinga.com/files/images/story/2025/1741813417_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Airlines Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jamie Baker</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$120.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to United Airlines Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Airlines Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Airlines Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into United Airlines Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Airlines Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind United Airlines Holdings</h2>
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.
<h3>United Airlines Holdings: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining United Airlines Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.85% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: United Airlines Holdings's net margin excels beyond industry benchmarks, reaching 6.7%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): United Airlines Holdings's ROE excels beyond industry benchmarks, reaching 8.16%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): United Airlines Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: United Airlines Holdings's debt-to-equity ratio is below the industry average at 2.65, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: United Airlines Holdings In The Eyes Of 9 Experts

Comments

Franklin FTSE Germany ETF

ニュース

最新ニュース Franklin FTSE Germany ETF (ARCA:FLGR)

ニュース

パートナーシップ

ベンジンガ・グローバル